Bispecific Antibodies
Despite their therapeutic potential, the adoption and utilization of bispecific antibodies exhibit significant disparities, particularly between urban and rural healthcare settings. Read More ›
The addition of a novel bispecific antibody to preactivated and expanded natural killer (NK) cells may represent an effective therapy for pretreated patients with relapsed or refractory CD30-positive lymphoma, according to preliminary findings from a phase 1/2 clinical trial presented during the 2022 American Association for Cancer Research Annual Meeting. Read More ›
Data from the ongoing phase 1/2 MajesTEC-1 study suggested that treatment with the BCMA x CD3 bispecific antibody teclistamab induced deep and durable responses in heavily pretreated patients with RRMM, with a manageable safety profile. Read More ›
Along with surgery, radiation, chemotherapy, and targeted therapy, immunotherapy has emerged as the fifth pillar of cancer treatment and is revolutionizing cancer treatment across the board. Read More ›
By Wayne Kuznar
A bispecific chimeric antigen receptor (CAR) T-cell product directed against CD19 and CD22 antigens induced a complete response (CR) in 5 of 12 (42%) evaluable children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL). Read More ›